Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus

Robert J Chilton

Research output: Contribution to journalArticle

Abstract

Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54% reduction in the risk of cardiovascular events, mainly driven by a 73% reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).

Original languageEnglish (US)
Pages (from-to)345-349
Number of pages5
JournalExpert Review of Endocrinology and Metabolism
Volume8
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

glimepiride
Type 2 Diabetes Mellitus
Metformin
Therapeutics
Dipeptidyl-Peptidase IV Inhibitors
Safety
Risk Reduction Behavior
Hypoglycemia
Linagliptin
Weight Loss
Stroke

Keywords

  • dipeptidyl peptidase-4 inhibitor
  • glimepiride
  • linagliptin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. / Chilton, Robert J.

In: Expert Review of Endocrinology and Metabolism, Vol. 8, No. 4, 07.2013, p. 345-349.

Research output: Contribution to journalArticle

@article{d95da62e5c8d4adda73fd9c1c8bef79a,
title = "Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus",
abstract = "Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54{\%} reduction in the risk of cardiovascular events, mainly driven by a 73{\%} reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).",
keywords = "dipeptidyl peptidase-4 inhibitor, glimepiride, linagliptin, Type 2 diabetes",
author = "Chilton, {Robert J}",
year = "2013",
month = "7",
doi = "10.1586/17446651.2013.811849",
language = "English (US)",
volume = "8",
pages = "345--349",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus

AU - Chilton, Robert J

PY - 2013/7

Y1 - 2013/7

N2 - Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54% reduction in the risk of cardiovascular events, mainly driven by a 73% reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).

AB - Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54% reduction in the risk of cardiovascular events, mainly driven by a 73% reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).

KW - dipeptidyl peptidase-4 inhibitor

KW - glimepiride

KW - linagliptin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84881111454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881111454&partnerID=8YFLogxK

U2 - 10.1586/17446651.2013.811849

DO - 10.1586/17446651.2013.811849

M3 - Article

AN - SCOPUS:84881111454

VL - 8

SP - 345

EP - 349

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 4

ER -